Key Study Information:
-
Treatment Area:
Parkinson's Disease
-
Study Aim:
To advance our understanding of Parkinson’s Disease and accelerate the development of advanced therapies to improve outcomes for patients.
-
Sponsor/Owner:
Queen Mary University of London
-
Goal:
Ongoing patient recruitment of patient's diagnosed with Parkinson's Disease.
Key Study Information:
-
Treatment Area:
Multiple Sclerosis
-
Study Aim:
To discover whether the genes that contribute to MS risk are the same or different for people of non-European ancestry, with a focus on people from African & South Asian backgrounds.
-
Sponsor/Owner:
Queen Mary University of London
-
Goal:
400 patients
Key Study Information:
-
Treatment Area:
Alopecia Areata
-
Study Aim:
To assess the safety, efficacy & dose response characterisation of STSO1 (Dithranol/ProSilic) administered topically, once daily, to affected scalp areas for 6 months, in patients who have mild to moderate Alopecia Areata.
-
Sponsor/Owner:
Soterios
-
Goal:
100 patients with mild to moderate Alopecia
Key Study Information:
-
Treatment Area:
Chronic Kidney Disease and Pruritus
-
Study Aim:
To evaluate the efficacy and safety of MC2-25 Cream and MC2-25 vehicle in subjects with chronic kidney disease-associated pruritus (CKD aP).
-
Sponsor/Owner:
MC2 Therapeutics
-
Goal:
22 Patients: Non-Dialysis CKD stage 3.
22 Patients: Non-dialysis CKD stage 4/5.
Total: 44 Patients
Key Study Information:
-
Treatment Area:
Asthma
-
Study Aim:
To understand the safety and efficacy of the drug AZD1402 in adults with moderate asthma, who regularly use inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs).
-
Sponsor/Owner:
AstraZeneca
-
Goal:
20 patients
Key Study Information:
-
Treatment Area:
COPD
-
Study Aim:
A study to discover whether a new investigational medication (Tozorakimab) could help reduce the number of exacerbations for people with COPD.
-
Sponsor/Owner:
AstraZeneca
-
Goal:
30+ patients with symptomatic COPD
Key Study Information:
-
Treatment Area:
RSV
-
Study Aim:
To understand how strongly babies can be protected from serious illness due to RSV infection (respiratory syncytial virus) by giving them a single antibody dose.
-
Sponsor/Owner:
LabCorp/SANOFI
-
Goal:
Aims to recruit 12,000 babies <1 year old